learndrugs
Musculoskeletal

Gout

High-yield Verified · Sep 2026

Gout is defined by the deposition of monosodium urate monohydrate crystals in joints and periarticular tissues. It is usually preceded by hyperuricaemia — a serum urate above 6.8 mg/dL, the concentration at which urate supersaturates and can crystallise.

The disorder behind the toe that cannot bear a bedsheet, the normal uric acid that proves nothing, the flare caused by starting the treatment, and four diet recommendations that are all conditional.

What’s going wrong in the body

The normal physiology, where it fails, and why the body’s compensation backfires.

01 Urate in, urate out, and one physical limit

Urate is a waste product of purines, and purines are unavoidable. "Purines perform essential functions in ALL living cells through purine-based nucleic acids, including adenine, guanine, and hypoxanthine. The contribution of dietary purines to the urate pool is significant. Removing purines from the diet of normal individuals for 10 days REDUCES URATE LEVELS BY 25%." That 25% figure is the honest ceiling on what diet alone can achieve, and it explains in advance why every dietary recommendation later on this page is graded conditional rather than strong. The other three-quarters comes from the body’s own cell turnover — which is why high-turnover states — "lymphoproliferative diseases, myeloproliferative disease," hemolysis and tumor lysis — appear on the risk list.

There are two exits, and the main one fails first. "When renal urate excretion is impaired, INTESTINAL URICOLYSIS compensates for up to HALF of total urate disposal, with the ABCG2 transporter playing a key role." The kidney is the main exit and the gut is the backup — which is why chronic kidney disease sits on both sides of this disease, and why a list of ordinary drugs that retain urate becomes a list of gout risk factors: "THIAZIDE/LOOP DIURETICS, LOW-DOSE ASPIRIN, CYCLOSPORINE, TACROLIMUS, PYRAZINAMIDE, ETHAMBUTOL."

Now the number the whole disease turns on, and it is physics rather than policy. "Gout is usually preceded by hyperuricemia, defined as a plasma or serum urate concentration exceeding 6.8 mg/dL," and "serum urate concentrations above 6.8 mg/dL result in SUPERSATURATION, increasing the risk of crystal deposition." The chapter states the principle outright: "Regardless of the trigger, the FINAL COMMON PATHWAY IS URATE SUPERSATURATION." 6.8 mg/dL is a solubility limit, not a guideline threshold — which matters, because two other urate numbers circulate and each answers a different question. 8 mg/dL or more is one chapter’s figure for "diagnostic of hyperuricemia." And a high level is not the disease: hyperuricemia "does not cause health problems for everyone." Below 6 mg/dL is the American College of Rheumatology’s 2020 treatment target — deliberately set under the solubility limit so that deposited crystals dissolve. Never print one of these without saying which question it answers.

One pathway, three numbers. Urate crystallises above a physical solubility limit of 6.8 mg/dL, and the treatment target of below 6 sits under that limit deliberately — the third figure belongs to a different question and a different owner.

02 Why this joint, why at three in the morning, and why it looks like sepsis

Supersaturation permits crystals; local conditions decide where and when. "The formation of MSU crystals requires SUSTAINED urate supersaturation. Factors such as the presence of PARTICULATE SEEDS, LOCAL CATION CONCENTRATIONS, pH, TEMPERATURE, and DEHYDRATION influence crystal formation. Immunoglobulin G may also facilitate crystal formation and growth." Temperature is the sourced reason the great toe goes first — it is the coolest, most distal, most load-bearing joint in the body, and the first metatarsophalangeal joint accounts for about 50% of initial attacks, with nearly 90% of patients developing podagra at some point. Under the microscope the crystals are "a ROD or long, NEEDLE-SHAPED crystal with NEGATIVE BIREFRINGENCE" seen on compensated polarized light microscopy, and they are "often INTRACELLULAR, indicating ACTIVE PHAGOCYTOSIS."

Phagocytosis of the crystals is the flare. The joint becomes "WARM, ERYTHEMATOUS, AND SWOLLEN… EXTREMELY TENDER TO TOUCH," with an "ABRUPT ONSET of severe pain, redness, and swelling, PEAKING WITHIN 12 TO 24 HOURS." The timing is characteristic: "Gout flares are MORE COMMON AT NIGHT AND IN THE EARLY MORNING HOURS. The pain is often SUDDEN, WAKING THE PATIENT FROM SLEEP." And the inflammation does not respect the joint capsule — "Signs of inflammation may extend BEYOND THE JOINT involved, giving the impression of CELLULITIS with erythema and desquamation. Systemic inflammatory features may include FEVER, MALAISE, AND FATIGUE," while in advanced disease "flares may become systemic, occasionally MIMICKING SEPSIS." That mimicry is the clinical danger of this page: acute gout "may be associated with FEVER AND LEUKOCYTOSIS, making it DIFFICULT TO DIFFERENTIATE FROM SEPTIC ARTHRITIS."

The flare ends on its own, and that is the trap. "The initial attack RESOLVES WITHIN 3 TO 14 DAYS, EVEN WITHOUT TREATMENT," yet "around 60% OF PATIENTS EXPERIENCE A SECOND ATTACK WITHIN 1 YEAR, AND 80% WITHIN 3 YEARS." What gets it started is a list of ordinary events, which is why gout so often flares in an inpatient admitted for something else: "LOCAL TRAUMA, ALCOHOL BINGES, OVEREATING OR FASTING, WEIGHT CHANGES, USE OF DIURETICS, and INITIATION OF URATE-LOWERING DRUGS. In a hospital setting, POSTOPERATIVE STATUS or acute severe medical illnesses such as MYOCARDIAL INFARCTION, EXACERBATION OF CONGESTIVE HEART FAILURE, or CEREBROVASCULAR ACCIDENT may precipitate attacks," with dehydration and starvation named alongside them. Read that list once more and notice the paradox sitting in the middle of it: starting the drug that treats the disease can set off the attack.

From solubility to a hot toe at three in the morning. The same inflammatory intensity that makes the flare unmistakable is what makes it indistinguishable from infection — and the trigger list includes the treatment itself.

03 Four stages — and why feeling well is not remission

Stage one is silent. Asymptomatic hyperuricaemia, and the ACR defines the boundary carefully: patients "with evidence of monosodium urate monohydrate deposition on advanced imaging may still be considered ASYMPTOMATIC if they have NOT had a prior gout flare or subcutaneous tophi." Stage two is the flare — monoarticular, abrupt, lower-limb in 85% to 90% of cases, self-limiting in 3 to 14 days. Stage three is the one that matters most and gets the least attention: "After resolving the acute attack, the patient enters the INTERCRITICAL stage. Patients typically feel WELL during this stage without experiencing joint pain or swelling. DESPITE THE APPARENT INACTIVITY OF THE DISEASE, HYPERURICEMIA PERSISTS, AND CRYSTAL DEPOSITION CONTINUES. Subclinical inflammation may be present in the joints during this period. If left untreated, the intercritical period SHORTENS with more active flare-ups." Crystals can be found in the joint between attacks — which is the diagnostic proof that the disease never stopped.

Stage four is the damage. "Tophi — FIRM, SUBCUTANEOUS DEPOSITS OF MSU CRYSTALS — develop in individuals with LONGSTANDING hyperuricemia and are most often found around the JOINTS, EARS, FINGER PADS, TENDONS, AND BURSAE," appearing as "CHALK-LIKE SUBCUTANEOUS NODULES beneath transparent skin" that "MAY OR MAY NOT DRAIN." Histologically a tophus is a granuloma: it has "the CRYSTALLINE CENTER, the surrounding CORONA ZONE, and the FIBROVASCULAR ZONE," with the corona containing "MULTINUCLEATED GIANT CELLS, HISTIOCYTES, and plasma" cells — "FOREIGN BODIES SURROUNDED BY GRANULOMAS." Timing: "chronic tophaceous gout usually develops 10 OR MORE YEARS after an acute attack," though "microtophi can be observed early" and some patients "present with tophi as their INITIAL symptom." The endpoint is blunt: "DESTRUCTIVE DEFORMING ARTHRITIS, EXTENSIVE BONE DESTRUCTION, AND SEVERE DEFORMITIES."

Two details make tophi more than a late-stage curiosity. First, they are systemic: "tophaceous deposits have been documented in various uncommon sites, including the CORNEA and HEART VALVES," underscoring "the SYSTEMIC nature of gout." Second, they sit on the exact anatomy that defines a different disease: "WOMEN DEVELOP TOPHACEOUS DEPOSITS ON THE HEBERDEN NODES AND BOUCHARD NODES. FINGER PAD TOPHI were observed in 30% of patients with chronic tophaceous gout. POSTMENOPAUSAL WOMEN WITH CKD may exhibit finger pad tophi BEFORE the onset of an acute attack." A knuckle nodule in an older woman is not automatically osteoarthritis. And the whole staging model exists to justify one decision: a single subcutaneous tophus is a STRONG American College of Rheumatology indication to start urate-lowering therapy — because by then the intercritical period has been doing its work for years.

The four stages, and the argument they make. Because deposition continues silently through the intercritical period, the absence of pain is not evidence of control — which is why the indications to start urate-lowering therapy are written around damage and flare frequency rather than around symptoms.

Causes & risk factors

Modifiable factors are teaching targets — the patient can act on them.

Chronic kidney disease — the main exit for urate is renal, and CKD is both a cause and a consequence of the disease; ACR notes that in CKD "there is a higher likelihood of gout progression and development of clinical tophi" Hypertension, obesity, metabolic syndrome, diabetes and hyperlipidaemia — named as a group on the risk-factor table, with comorbidity prevalence rising as serum urate rises modifiable Thiazide and loop diuretics — named urate-raising drugs, and starting a diuretic is separately named as a flare precipitant modifiable Low-dose aspirin, cyclosporine, tacrolimus, pyrazinamide and ethambutol — the rest of the sourced urate-raising medication list modifiable Alcohol, ranked — "ALCOHOL (BEER > SPIRITS > WINE)"; limiting or abstaining was associated with serum urate 1.6 mg/dL lower, and more than one to two drinks with a 40% higher risk of a flare modifiable Red and organ meats, shellfish — the named high-purine foods; note that removing dietary purines entirely for ten days lowers urate by only 25% modifiable Fructose-sweetened beverages and high-fructose corn syrup — greater consumption was associated with a higher risk of incident gout in the Nurses’ Health Study modifiable Older age and male sex — gout affects "5.9% of men and 2% of women" in the United States, it is "more common in men, especially as they get older," and after menopause women's urate rises "to levels comparable to those in adult men" Adult weight gain — "consistently associated with an increased risk of gout," with obesity at a BMI above 35 kg/m² present in 29% of gout patients versus 10% of the general population in the Olmsted County data modifiable Comorbidities and high cell-turnover states — kidney problems, diabetes, high blood pressure and high cholesterol (NHS), and states of "high cell breakdown or turnover" such as lymphoproliferative and myeloproliferative disease, hemolysis and tumor lysis Genetic predisposition — named as a risk factor, and the ACR voting panel specifically discussed "the important GENETIC contributions to the development and severity of hyperuricemia and gout" Two rare X-linked enzyme defects — "deficiency of the salvage enzyme HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE (HGPRT)" and "OVERACTIVITY OF PRPP SYNTHETASE"; such "rare single-gene enzyme defects cause EARLY-ONSET OR SEVERE disease" Dehydration, fasting and starvation — named both as factors in crystal formation and as flare precipitants modifiable Surgery and acute medical illness — "POSTOPERATIVE STATUS or acute severe medical illnesses such as MYOCARDIAL INFARCTION, EXACERBATION OF CONGESTIVE HEART FAILURE, or CEREBROVASCULAR ACCIDENT," which is why gout flares happen to inpatients admitted for something else

Signs & symptoms

Each finding tied to the mechanism that produces it — and the triage it calls for.

One joint, abrupt onset, peaking within 12 to 24 hours Hold & notify
Why: "The initial clinical presentation of gout is an acute episode of MONOARTICULAR arthritis, typically with ABRUPT ONSET of severe pain, redness, and swelling, PEAKING WITHIN 12 TO 24 HOURS." 85% to 90% of cases affect the lower limbs, and "AXIAL INVOLVEMENT, including the sacroiliac joints and spine, is UNCOMMON." Speed is itself a diagnostic feature — rheumatoid arthritis is insidious and osteoarthritis degenerates over years.
Podagra — the first metatarsophalangeal joint Hold & notify
Why: "THE FIRST METATARSOPHALANGEAL JOINT IS THE MOST COMMON SITE, accounting for approximately 50% OF INITIAL ATTACKS (PODAGRA), and NEARLY 90% OF PATIENTS DEVELOP PODAGRA during the course of the disease." Other common sites are "the ANKLE, KNEE, AND TARSAL JOINTS, as well as TENDONS AND BURSAE." The mechanism explains the site: temperature is one of the named factors in crystal formation, and the great toe is the coolest, most distal joint there is.
A warm, red, swollen joint that cannot bear the weight of a bedsheet Hold & notify
Why: The clinical description is "a WARM, ERYTHEMATOUS, AND SWOLLEN joint that is EXTREMELY TENDER TO TOUCH," and patient advice makes it concrete: "try to keep bedclothes off the affected joint at night." That advice is a nursing instruction in disguise — it is the rationale for a bed cradle, for keeping linen off the foot, and for how the limb is handled in transfers.
Pain that starts in the night and wakes the patient Expected
Why: "Gout flares are MORE COMMON AT NIGHT AND IN THE EARLY MORNING HOURS. The pain is often SUDDEN, WAKING THE PATIENT FROM SLEEP, or it may have developed gradually over a few hours before presentation." The patient version: flares "often start suddenly at night," with "intense pain, which may be bad enough to wake you up."
❗ Fever, leukocytosis and skin changes that look like cellulitis Report immediately
Why: This is the most dangerous finding on the page, because it is the one that makes gout indistinguishable from infection. "Acute gouty arthritis may be associated with FEVER AND LEUKOCYTOSIS, making it DIFFICULT TO DIFFERENTIATE FROM SEPTIC ARTHRITIS," and "signs of inflammation may extend BEYOND THE JOINT involved, giving the impression of CELLULITIS with erythema and desquamation. Systemic inflammatory features may include FEVER, MALAISE, AND FATIGUE." In advanced disease "flares may become systemic, occasionally MIMICKING SEPSIS." Fever in a hot joint is a reason to aspirate, not a reason to conclude.
A flare that settles by itself in a few days early Expected
Why: "The initial attack RESOLVES WITHIN 3 TO 14 DAYS, EVEN WITHOUT TREATMENT." Spontaneous resolution is why the disease gets undertreated — and the natural history says what happens next: "around 60% OF PATIENTS EXPERIENCE A SECOND ATTACK WITHIN 1 YEAR, AND 80% WITHIN 3 YEARS," and over time "gout flares may become LESS SEVERE but may involve MORE JOINTS."
Feeling completely well between attacks Hold & notify
Why: The intercritical stage, and the single most important concept on this page. "Patients typically feel WELL during this stage… DESPITE THE APPARENT INACTIVITY OF THE DISEASE, HYPERURICEMIA PERSISTS, AND CRYSTAL DEPOSITION CONTINUES. Subclinical inflammation may be present in the joints during this period. If left untreated, the intercritical period SHORTENS with more active flare-ups." Crystals can be aspirated from a quiet joint, which is the objective proof that nothing stopped.
More than four joints involved at once late Hold & notify
Why: The sourced definitions: "When MORE THAN 4 joints are affected, the pattern is described as POLYARTICULAR gout; if 4 OR FEWER are involved, it is OLIGOARTICULAR." Separately, "polyarticular gout flares are more likely to occur in patients with LONGSTANDING disease." A polyarticular presentation is therefore a marker of how long the disease has been running unchecked — and it is also the presentation most likely to mimic sepsis.
Firm, chalky subcutaneous nodules that may drain late Hold & notify
Why: Tophi — "FIRM, SUBCUTANEOUS DEPOSITS OF MSU CRYSTALS" found "around the JOINTS, EARS, FINGER PADS, TENDONS, AND BURSAE," appearing as "CHALK-LIKE SUBCUTANEOUS NODULES beneath transparent skin with increased vascularity" that "MAY OR MAY NOT DRAIN" chalky material. They usually appear "10 OR MORE YEARS after an acute attack," though microtophi appear early and some patients present with tophi first. Clinically, one tophus is a strong indication to start urate-lowering therapy.
Nodules on the Heberden and Bouchard nodes of an older woman late Hold & notify
Why: A direct trap for the osteoarthritis comparison. "WOMEN DEVELOP TOPHACEOUS DEPOSITS ON THE HEBERDEN NODES AND BOUCHARD NODES. FINGER PAD TOPHI were observed in 30% of patients with chronic tophaceous gout. POSTMENOPAUSAL WOMEN WITH CKD may exhibit finger pad tophi BEFORE the onset of an acute attack." The two diseases can occupy the same knuckle, and in this group the tophus can arrive before any flare has ever happened.
Destructive, deforming arthritis with bone loss late Hold & notify
Why: The endpoint of untreated deposition: chronic tophaceous gout "leads to DESTRUCTIVE DEFORMING ARTHRITIS, EXTENSIVE BONE DESTRUCTION, AND SEVERE DEFORMITIES." The patient version names the functional cost: untreated repeated attacks can lead to "damage in your joints," and tophi "can also cause bone and soft tissue damage and misshapen joints."

Diagnostics

Test In this disorder Normal
Arthrocentesis with compensated polarized light microscopy This is the gold standard — "MSU CRYSTAL IDENTIFICATION REMAINS THE GOLD STANDARD FOR DIAGNOSING GOUT." Arthrocentesis is "ESSENTIAL to confirm the diagnosis and differentiate it from other conditions such as SEPTIC ARTHRITIS, LYME DISEASE, or PSEUDOGOUT (caused by CALCIUM PYROPHOSPHATE crystals)." And the technique also works between attacks — it "can also identify uric acid crystals from tophaceous deposits AND JOINTS DURING THE INTERCRITICAL PERIOD," which is how the intercritical stage is proved rather than assumed. NEEDLE-SHAPED, NEGATIVELY BIREFRINGENT crystals, "often INTRACELLULAR, indicating ACTIVE PHAGOCYTOSIS." The fluid in a flare is "typically YELLOW AND CLOUDY, containing crystals and white blood cells, predominantly NEUTROPHILS" —
Gram stain, culture and synovial glucose — sent on the same sample ❗ Read the caveats, because they overturn the usual shortcut. "THERE IS CONSIDERABLE OVERLAP IN WBC COUNTS AND NEUTROPHIL PERCENTAGES between patients with acute gouty arthritis and those with septic arthritis, RENDERING THESE PARAMETERS UNRELIABLE for diagnosis." And decisively: "IT IS ESSENTIAL TO NOTE THAT THE PRESENCE OF CRYSTALS IN SYNOVIAL FLUID ANALYSIS DOES NOT RULE OUT SEPTIC ARTHRITIS, AS BOTH CONDITIONS CAN COEXIST" — corroborated elsewhere as "multiple etiologies can co-exist, and the presence of gout does not rule out the presence of concomitant infection." Send the Gram stain and culture regardless of what the crystals show. In septic arthritis the fluid is "MORE OPAQUE, with a YELLOW-GREEN appearance," with "a HIGHER WBC COUNT (> 50,000/microL)" and neutrophil predominance, and "POSITIVE SYNOVIAL FLUID GRAM STAINS AND CULTURES, along with LOW SYNOVIAL FLUID GLUCOSE" —
Serum uric acid — during a flare ❗❗ The most examinable diagnostic fact on this page, and the source states it as a rule: "SERUM URIC ACID MEASUREMENT DURING AN ACUTE ATTACK IS OF NO DIAGNOSTIC VALUE; IT IS MOST USEFUL WHEN CHECKED AFTER THE RESOLUTION OF THE FLARE." So a normal level does not exclude gout and a high level does not confirm it — remember that hyperuricemia "does not cause health problems for everyone." The serum urate has a different job entirely, further down this page: it is the treat-to-target monitoring value once urate-lowering therapy starts. "During acute gouty arthritis, the serum urate level may be HIGH, NORMAL, OR LOW. Approximately 50% OF PATIENTS WITH ACUTE GOUTY ARTHRITIS DO NOT HAVE AN ELEVATED SERUM URIC ACID LEVEL" —
White cell count, ESR and C-reactive protein "These features are NONSPECIFIC and DO NOT CONFIRM OR DIFFERENTIATE the diagnosis from SEPTIC ARTHRITIS." They tell you the joint is inflamed, which the bedside already told you. The inflammatory markers and their kinetics are owned by the inflammation page; here their role is simply that they cannot settle the question the aspiration settles. "Elevations in the WBC count, erythrocyte sedimentation rate, and C-reactive protein levels during acute gouty arthritis" —
Joint x-ray Imaging supports the diagnosis; it does not replace the aspiration. And when radiographic damage attributable to gout is present by any imaging modality, that finding is by itself a strong ACR indication to start urate-lowering therapy. Radiographs "may show gouty erosions," often described as "rat bite" or "punched-out" erosions with thin overhanging edges; ultrasonography and dual-energy CT can assist —
Urinary uric acid crystals and urine pH Different crystal shape, different organ, same chemistry. Gout and uric acid nephrolithiasis are named as "the 2 most common complaints associated with hyperuricemia," and uric acid stones result "from the accumulation of uric acid crystals in the kidneys," which "often correlates with elevated uric acid levels in the bloodstream." Urolithiasis is also one of the conditional ACR indications to start urate-lowering therapy even after a first flare. "Urinary uric acid will form crystals if urine pH is ACIDIC (< 5.5). These YELLOWISH-BROWN crystals can be RHOMBOID or cluster to create a ROSETTE shape" —
Arthrocentesis — the procedure itself Two practical limits to expect. "Unsuccessful aspiration is COMMON, as synovium can CLOG THE NEEDLE," and "nonsterile technique can contaminate the collected fluid" — which matters doubly here, because a contaminated sample cannot answer the septic-arthritis question. Complications are "rare, and those that do occur are typically not severe": seeding a skin infection into the joint, rare cartilage damage, pain or local ecchymosis at the site, bleeding and iatrogenic haemarthrosis, and skin reaction to antiseptic or dressing adhesive. Synovial fluid "collected by penetrating the joint space through aspiration… under STERILE procedural conditions," because "sterility is essential NOT ONLY to prevent transmission of infection BUT ALSO to ensure accurate fluid analysis" —

Complications

Warning: Missed septic arthritis Report immediately
The most dangerous complication of a confident gout diagnosis. Fever and leukocytosis occur in gout itself, the fluid cell counts overlap "considerably," and "the presence of crystals in synovial fluid analysis DOES NOT RULE OUT septic arthritis, as BOTH CONDITIONS CAN COEXIST."
Heralding cues: a first-ever presentation, fever with rigors or systemic toxicity, a joint that does not follow the expected 3-to-14-day course, or any plan to inject a steroid into the joint. The nursing action is to make sure the joint is aspirated with Gram stain and culture sent before an intra-articular glucocorticoid goes in — because injecting steroid into an infected joint is a different and much worse problem than a delayed gout diagnosis.
Warning: Chronic tophaceous gout with joint destruction Hold & notify
"DESTRUCTIVE DEFORMING ARTHRITIS, EXTENSIVE BONE DESTRUCTION, AND SEVERE DEFORMITIES," developing "10 OR MORE YEARS after an acute attack" in untreated or undertreated patients,, with "damage in your joints" (NHS) and "misshapen joints" (MedlinePlus).
The heralding cues arrive years before the deformity and are all easy to dismiss: the intercritical intervals get shorter, each flare involves more joints, and the first firm nodule appears at an ear, a finger pad, a tendon or a bursa. Any one of those should prompt the urate-lowering conversation, because one subcutaneous tophus is already a strong indication to treat.
Warning: Uric acid kidney stones Hold & notify
Gout and uric acid nephrolithiasis are "the 2 most common complaints associated with hyperuricemia." Stones form when urine pH falls below 5.5, and present as "renal colic or severe, acute flank, abdominal, or back pain, often radiating to the groin; hematuria or brownish-colored urine."
Urolithiasis changes the treatment decision: it is one of the three conditional ACR indications to start urate-lowering therapy even after a first flare, alongside CKD stage 3 or worse and a serum urate above 9 mg/dL. The rationale ACR gives is concrete — in urolithiasis, allopurinol and febuxostat "lower 24-hour urinary uric acid excretion more than placebo."
Warning: Chronic kidney disease, on both sides of the relationship Hold & notify
CKD impairs the main exit for urate and so causes hyperuricaemia; hyperuricaemia and gout then complicate CKD. ACR notes that in CKD "there is a higher likelihood of gout progression and development of clinical tophi," that "treatment options for gout FLARE are LIMITED in this population," and that "there may be added benefit of using ULT to prevent progression of renal disease."
The practical squeeze is that CKD removes options at exactly the moment it increases need. NSAIDs become unattractive, which narrows a three-option flare menu to two. Allopurinol, however, stays first-line — explicitly including CKD stage above 3 — and a xanthine oxidase inhibitor is strongly recommended over probenecid in that group. The starting dose goes lower, not the drug choice.
Caution: The cardiometabolic cluster
Gout travels with "OBESITY, HYPERTENSION, CKD, DIABETES MELLITUS, HYPERLIPIDEMIA, and METABOLIC SYNDROME," and United Kingdom and German studies additionally linked it to "congestive heart failure and myocardial infarction," with comorbidity prevalence rising as serum urate rises.
Two consequences follow for practice. The comorbidities are the patient factors that decide which of the three flare treatments is safe — chronic kidney disease, heart failure, hypertension and diabetes each bear on an NSAID or a glucocorticoid. And obesity is itself modifiable: "adult weight gain is consistently associated with an increased risk of gout," which is why a weight-loss programme is conditionally recommended for patients who are overweight or obese.
Caution: Systemic mimicry and unusual deposits Hold & notify
Periarticular spread gives "the impression of CELLULITIS with erythema and desquamation," polyarticular flares can be "occasionally MIMICKING SEPSIS," and tophaceous deposits are documented "including the CORNEA and HEART VALVES."
The organ deposits "underscore the SYSTEMIC nature of gout and its capacity to affect various tissues and organs beyond the joints." For the bedside the mimicry matters more: a red, hot, spreading area over an inflamed joint in a patient with known gout is not automatically cellulitis, and treating it as such without aspirating the joint leaves both the gout and a possible septic arthritis unaddressed.

Medications for this condition

Why each class is prescribed here — every card links to its full pharmacology page.

Antigout Agents First-line
Musculoskeletal · allopurinol

This class does two entirely different jobs, and confusing them is the commonest error on the page. Urate-lowering therapy treats the DISEASE by removing the substrate. Colchicine treats or prevents the FLARE. Neither substitutes for the other. WHO STARTS URATE-LOWERING THERAPY — a STRONG ACR 2020 recommendation: "Initiating ULT is STRONGLY recommended for gout patients with ANY of the following: ≥ 1 SUBCUTANEOUS TOPHI; EVIDENCE OF RADIOGRAPHIC DAMAGE (ANY MODALITY) ATTRIBUTABLE TO GOUT; OR FREQUENT GOUT FLARES, WITH FREQUENT BEING DEFINED AS ≥ 2 ANNUALLY." It is conditionally recommended for patients with more than one flare but fewer than two a year, and conditionally recommended AGAINST after a first flare — "HOWEVER, initiating ULT is CONDITIONALLY RECOMMENDED for patients with comorbid MODERATE-TO-SEVERE CKD (STAGE ≥ 3), SU CONCENTRATION > 9 mg/dl, OR UROLITHIASIS." WHICH AGENT — STRONG: "we STRONGLY recommend ALLOPURINOL OVER ALL OTHER ULT AS THE PREFERRED FIRST-LINE AGENT FOR ALL PATIENTS, INCLUDING IN THOSE WITH CKD STAGE > 3," with a xanthine oxidase inhibitor strongly preferred over probenecid in that group, and pegloticase strongly recommended against as first-line. START LOW — STRONG: a low starting dose with titration to target; the guideline states 100 mg/day or less for allopurinol and lower in CKD, with 50 mg/day or less considered there, and under 40 mg/day for febuxostat (probenecid 500 mg once or twice daily is a conditional recommendation). The reason is explicit: "A LOWER STARTING DOSE OF ANY ULT REDUCES THE RISK OF FLARE ASSOCIATED WITH INITIATION," and the Patient Panel accepted "MORE BLOOD DRAWS AND PROVIDER VISITS" to get it. TREAT TO TARGET — STRONG, high certainty: titration "guided by SERIAL SU VALUES" over a fixed dose, "CONTINUING ULT TO ACHIEVE AND MAINTAIN AN SU TARGET OF < 6 mg/dl over no target," paced over "WEEKS TO MONTHS, NOT YEARS, to prevent TREATMENT INERTIA" — and note that ACR removed the extra thresholds its own 2012 guideline carried. Continuing indefinitely is conditional with very low certainty. FLARE PROPHYLAXIS WHEN STARTING — STRONG, twice: concomitant anti-inflammatory prophylaxis (colchicine, an NSAID, or prednisone/prednisolone) continued 3 to 6 months, because "SHORTER DURATIONS WERE ASSOCIATED WITH FLARES UPON CESSATION." TESTING — CONDITIONAL: HLA-B*5801 before allopurinol in patients of Southeast Asian descent (Han Chinese, Korean, Thai) and African American patients, because the allele carries "a MARKEDLY ELEVATED RISK for" allopurinol hypersensitivity syndrome; universal testing in other groups is conditionally recommended against. COLCHICINE FOR THE FLARE — STRONG: low-dose over high-dose "given its SIMILAR EFFICACY AND FEWER ADVERSE EFFECTS," following "FDA-approved dosing… (1.2 mg IMMEDIATELY FOLLOWED BY 0.6 mg AN HOUR LATER)." The class page owns each agent’s pharmacology and interactions.
NSAIDs
Musculoskeletal · ibuprofen

One of three equally STRONG first-line options for the flare, and the page does not rank them. ACR 2020: "we STRONGLY recommend using ORAL COLCHICINE, NSAIDs, OR GLUCOCORTICOIDS (ORAL, INTRAARTICULAR, OR INTRAMUSCULAR) as appropriate FIRST-LINE therapy for gout flares over IL-1 inhibitors or ACTH (THE CHOICE OF COLCHICINE, NSAIDs, OR GLUCOCORTICOIDS SHOULD BE MADE BASED ON PATIENT FACTORS AND PREFERENCES)." So the examinable content is the choosing, not a ranking — and on a gout page the patient factors that decide it are the comorbidities gout travels with. Chronic kidney disease, heart failure, hypertension and diabetes are all on gout’s own risk list, and every one of them bears on whether an NSAID is safe. The practical framing the patient needs is speed: attacks "are usually treated with a non-steroidal anti-inflammatory (NSAID), like ibuprofen," taken "as soon as possible." NSAIDs are also one of the three named prophylaxis agents for the 3-to-6-month window after urate-lowering therapy starts. The class page owns the renal, gastrointestinal, bleeding and cardiovascular adverse effects; this page teaches that the gout patient is disproportionately likely to have the contraindications.
Corticosteroids
Endocrine · prednisone

The third of the three equally strong first-line flare options, and the one with the most routes. ACR 2020 names "glucocorticoids (ORAL, INTRAARTICULAR, OR INTRAMUSCULAR)," and the patient-facing description matches: if the pain and swelling do not improve, "you may be given steroids as tablets or an injection." The situation where they stop being one option among three and become the answer is the patient who cannot take anything by mouth — a STRONG recommendation: "For patients who may receive NPO, we STRONGLY recommend GLUCOCORTICOIDS (INTRAMUSCULAR, INTRAVENOUS, OR INTRAARTICULAR) over IL-1 inhibitors or ACTH." That is a real and common ward scenario, because postoperative status is itself a named flare precipitant. Prednisone or prednisolone is also one of the three named prophylaxis agents for the 3-to-6-month window. One disorder-side safety interaction belongs here rather than on the class page: before any intra-articular injection, be certain the joint is not septic, because "the presence of crystals in synovial fluid analysis does not rule out septic arthritis, as both conditions can coexist." The class page owns hyperglycaemia, infection risk, adrenal suppression and the taper.

Beyond medications

  • TOPICAL ICE during a flare — a conditional ACR 2020 recommendation with low certainty of evidence: "For patients experiencing a gout flare, we CONDITIONALLY recommend using TOPICAL ICE AS AN ADJUVANT TREATMENT over no adjuvant treatment." It is an adjuvant, not a substitute for drug treatment — but it is a genuine, guideline-named nursing intervention, and it costs nothing.
  • PROTECT THE JOINT FROM CONTACT. The sourced patient advice — "try to keep bedclothes off the affected joint at night" — is the rationale for a bed cradle, for keeping the linen off the foot, and for how the limb is supported during repositioning and transfers. It is also a useful way to gauge severity without touching the joint.
  • THE FOUR LIFESTYLE RECOMMENDATIONS ARE ALL CONDITIONAL — quote them as such. "LIMITING ALCOHOL INTAKE is conditionally recommended… regardless of disease activity. LIMITING PURINE INTAKE is conditionally recommended… regardless of disease activity. LIMITING HIGH-FRUCTOSE CORN SYRUP INTAKE is conditionally recommended… regardless of disease activity. USING A WEIGHT LOSS PROGRAM (NO SPECIFIC PROGRAM ENDORSED) is conditionally recommended for those patients with gout who are OVERWEIGHT/OBESE, regardless of disease activity." And one thing is recommended AGAINST: "Adding VITAMIN C supplementation is CONDITIONALLY RECOMMENDED AGAINST for patients with gout, regardless of disease activity."
  • ❗❗ HOW TO TEACH THE DIET — a primary-source instruction that matters more than the list. The ACR voting panel "discussed data demonstrating the important GENETIC contributions to the development and severity of hyperuricemia and gout and informally recommended that providers BE MINDFUL WHEN SOLICITING INFORMATION REGARDING THE DIETARY HABITS OF PATIENTS AND ENSURE THAT DISCUSSIONS REGARDING DIETARY RECOMMENDATIONS ARE NOT MISINTERPRETED AS ‘PATIENT-BLAMING,’ AS PATIENTS FREQUENTLY FEEL STIGMATIZED WHEN DISCUSSING GOUT WITH THEIR PROVIDERS. DIETARY MODIFICATIONS LIKELY YIELD ONLY SMALL CHANGES IN SU CONCENTRATION, BUT DIETARY FACTORS MAY SERVE AS TRIGGERS FOR FLARES, and patients frequently seek advice on dietary management." Teach the four measures as conditional flare-trigger avoidance, and never as a substitute for urate-lowering therapy.
  • What the evidence behind each measure actually shows. Alcohol: urate was "1.6 mg/dl LOWER" in those who limited or abstained, and more than one to two drinks carried "a 40% HIGHER RISK OF GOUT FLARE than periods without alcohol," with heavy drinkers more likely to keep flaring. Purines: a case-crossover study associated increasing purine intake with flare risk, "HOWEVER, a" study "focused on LOW PURINE INTAKE DID NOT DEMONSTRATE LOWER SU." Fructose: in the Nurses’ Health Study, greater high-fructose corn syrup consumption was associated with higher risk of incident gout. Read together with the finding that removing dietary purines entirely for ten days lowers urate by only 25%, the picture is consistent: diet moves flares more than it moves the number.
  • NURSE- AND PHARMACIST-LED PROTOCOLS ARE GUIDELINE-BACKED — a conditional recommendation with real trial evidence. "For all patients taking ULT, we CONDITIONALLY recommend delivery of an AUGMENTED PROTOCOL of ULT dose management BY NONPHYSICIAN PROVIDERS to optimize the treat-to-target strategy that includes PATIENT EDUCATION, SHARED DECISION-MAKING, and treat-to-target protocol." The evidence: a United Kingdom randomised trial in which "patients randomized to a NURSE-LED, treat-to-target protocol demonstrated GREATER ULT ADHERENCE, LOWER SU CONCENTRATIONS, REDUCTION IN TOPHI, AND A LOWER PROPORTION OF FREQUENT (≥ 2) GOUT FLARES AT 24 MONTHS," plus "Two separate PHARMACIST-LED interventions in the US… SUPERIOR to usual care in terms of treatment adherence, SU outcomes, and higher allopurinol dosing."
  • HYDRATION, with two distinct rationales. Dehydration is named as a factor in crystal formation and separately as a flare precipitant — and acidic urine below pH 5.5 is where urate precipitates into stones. A perioperative or acutely unwell patient who is fasting and underhydrated is being set up on all three fronts at once.
  • A note on history, used as a hook and not as an explanation. Gout "was historically called the ‘disease of kings’ because it was prevalent among the wealthy," and the name derives from the Latin for "drop," "reflecting the MEDIEVAL BELIEF that the condition resulted from a drop of ‘evil humo[ur].’" Today it affects "5.9% of men and 2% of women" in the United States, and the guideline panel emphasises the genetic contribution. The history is memorable; it is not a mechanism, and repeating it as one is exactly the stigma ACR asks providers to avoid.

Nursing considerations

The RN-specific layer — each action paired with the reason it matters.

Assessment & monitoring
Describe the joint the way the source does, and time the onset: abrupt, peaking within 12 to 24 hours, usually one lower-limb joint, often overnight.
Why: The sourced picture is a "warm, erythematous, and swollen joint that is EXTREMELY TENDER TO TOUCH," with "abrupt onset… peaking within 12 to 24 hours," 85% to 90% in the lower limbs, and flares "more common at night and in the early morning hours," often "waking the patient from sleep." The speed is diagnostic information: rheumatoid arthritis is insidious and osteoarthritis takes years, so a joint that went from normal to unbearable overnight narrows the field before any test is sent.
Do not send a serum uric acid to diagnose the flare, and do not reassure anyone on a normal one.
Why: "During acute gouty arthritis, the serum urate level may be HIGH, NORMAL, OR LOW. Approximately 50% of patients with acute gouty arthritis do NOT have an elevated serum uric acid level. SERUM URIC ACID MEASUREMENT DURING AN ACUTE ATTACK IS OF NO DIAGNOSTIC VALUE; it is most useful when checked AFTER the resolution of the flare." The diagnostic test is arthrocentesis with polarized microscopy. The serum urate becomes useful later, as the value that titrates urate-lowering therapy to target.
Escalate for possible septic arthritis — and make sure the joint is aspirated with Gram stain and culture sent before any intra-articular steroid.
Why: Three sourced facts stack against a confident bedside diagnosis. Gout itself causes "fever and leukocytosis, making it difficult to differentiate from septic arthritis." The synovial cell counts show "considerable overlap… rendering these parameters unreliable." And "the presence of crystals in synovial fluid analysis DOES NOT RULE OUT septic arthritis, as BOTH CONDITIONS CAN COEXIST." Report fever, rigors, systemic toxicity, or a first-ever presentation, and treat a plan to inject the joint as the moment the infection question must already be answered.
Review the medication list for urate-raising drugs and for anything newly started.
Why: The named list is "thiazide/loop diuretics, low-dose aspirin, cyclosporine, tacrolimus, pyrazinamide, ethambutol." Two entries do double duty: starting a diuretic and starting a urate-lowering drug are both named flare precipitants. So a new flare in a patient whose medicines changed last week is worth reporting as a medication event, not just as a gout event.
Monitor the treat-to-target value once urate-lowering therapy starts, and know the pacing.
Why: ACR 2020 strongly recommends titration "guided by SERIAL SU VALUES" over a fixed dose, and "continuing ULT to achieve and maintain an SU target of < 6 mg/dl" — a recommendation carrying high certainty of evidence. Titration should run "over a reasonable time frame (e.g., WEEKS TO MONTHS, NOT YEARS) to prevent ‘TREATMENT INERTIA’." That means repeated blood draws, and the guideline records that the Patient Panel explicitly accepted more draws and visits in exchange for safer low starting doses.
Interventions & safety
Keep the bedclothes off the joint — a cradle, a footboard, or however the unit does it.
Why: Sourced directly from patient advice: "try to keep bedclothes off the affected joint at night." This is not a comfort nicety in a joint that is "extremely tender to touch"; it also prevents the involuntary guarding and refused repositioning that follow an unnecessary contact.
Offer topical ice during the flare.
Why: ACR 2020 "CONDITIONALLY recommend[s] using TOPICAL ICE AS AN ADJUVANT TREATMENT over no adjuvant treatment," with low certainty of evidence. State it as what it is — a conditional, adjuvant recommendation — and give it alongside drug treatment rather than instead of it.
Know the NPO patient’s answer before the situation arises.
Why: "For patients who may receive NPO, we STRONGLY recommend GLUCOCORTICOIDS (INTRAMUSCULAR, INTRAVENOUS, OR INTRAARTICULAR) over IL-1 inhibitors or ACTH." This is a strong recommendation for a situation that occurs constantly, because postoperative status is itself a named flare precipitant — the patient most likely to flare is often the patient least able to swallow a tablet.
Keep the patient hydrated, particularly around surgery, fasting and acute illness.
Why: Dehydration appears twice in the sourced mechanism — as one of the factors influencing crystal formation, and again in the precipitant list alongside "overeating or fasting" and "starvation." It also matters for the kidney, where uric acid precipitates into stones when the urine is acidic, below pH 5.5.
Check whether HLA-B*5801 testing is indicated before allopurinol starts.
Why: "Testing for the HLA-B*5801 allele PRIOR TO STARTING ALLOPURINOL is CONDITIONALLY recommended for patients of SOUTHEAST ASIAN DESCENT (e.g., HAN CHINESE, KOREAN, THAI) and for AFRICAN AMERICAN patients," because the allele is "associated with a MARKEDLY ELEVATED RISK for" allopurinol hypersensitivity syndrome and is commoner in those groups. Universal testing in other backgrounds is conditionally recommended against — so this is a targeted question, not a routine one.
Patient teaching
Teach the paradox before it happens: starting the treatment can cause a flare, and that is expected.
Why: "Initiation of urate-lowering drugs" is on the sourced precipitant list, which is exactly why ACR strongly recommends concomitant anti-inflammatory prophylaxis — colchicine, an NSAID, or prednisone/prednisolone — continued 3 to 6 months rather than under 3, since "shorter durations were associated with flares upon cessation of prophylaxis," and why the starting dose is deliberately low, because "a lower starting dose of any ULT reduces the risk of flare associated with initiation." A patient who is not told this reads the first flare as proof the drug failed and stops it.
Do not stop urate-lowering therapy because of a flare — and know that the old rule about never starting during an attack has changed.
Why: Write what the guideline actually says. ACR strongly recommends continuing urate-lowering therapy to reach and hold a target below 6 mg/dL (high certainty), conditionally recommends continuing indefinitely (very low certainty), and conditionally recommends starting during a flare rather than waiting: "When the decision is made that ULT is indicated WHILE the patient is experiencing a gout flare, we CONDITIONALLY recommend STARTING ULT DURING THE GOUT FLARE over starting ULT AFTER the gout flare has resolved." Nothing in the guideline supports interrupting it for a flare.
Explain what the target number means, and which number it is not.
Why: Below 6 mg/dL is a therapeutic target, deliberately set under the 6.8 mg/dL solubility limit so that deposited crystals dissolve — it is not a "normal" value. Keep the other figures separate and attributed: 6.8 is the supersaturation threshold, 8 or more is one reference chapter’s diagnostic figure for hyperuricaemia, and a high level on its own "does not cause health problems for everyone." A below 5 mg/dL figure some patients will find online for visible tophi is not an ACR 2020 target; the guideline defines no such threshold, having deliberately removed the extra thresholds from its own 2012 edition.
Teach speed of treatment for the flare, and teach it before the next one.
Why: The patient-facing instruction is direct: "take any medicine you've been prescribed as soon as possible – it should start to work within 2 days." Set against a flare that otherwise runs 3 to 14 days, that is the argument for having the plan agreed and the medicine available in advance.
Deliver the lifestyle advice in the guideline’s own framing, so it is not heard as blame.
Why: ACR asks providers to "ENSURE THAT DISCUSSIONS REGARDING DIETARY RECOMMENDATIONS ARE NOT MISINTERPRETED AS ‘PATIENT-BLAMING,’ AS PATIENTS FREQUENTLY FEEL STIGMATIZED WHEN DISCUSSING GOUT WITH THEIR PROVIDERS," noting the genetic contribution, that "dietary modifications likely yield only SMALL changes in SU concentration," and that dietary factors work mainly as flare triggers. The four measures are all conditional — limit alcohol, limit purines, limit high-fructose corn syrup, and a weight-loss programme if overweight or obese — and vitamin C supplementation is conditionally recommended against.
Say plainly that feeling well between attacks is not the disease stopping.
Why: "DESPITE THE APPARENT INACTIVITY OF THE DISEASE, HYPERURICEMIA PERSISTS, AND CRYSTAL DEPOSITION CONTINUES," and untreated, "the intercritical period SHORTENS with more active flare-ups," with 60% of patients flaring again within a year and 80% within three. Crystals can be aspirated from a quiet joint, which is the objective version of the same point. This is the whole argument for a daily tablet in a person who currently has no symptoms — and without it, adherence has nothing to stand on.

How a real nurse thinks

The clinical-judgment loop, worked for a typical presentation — reasoning, not reference.

  1. 1
    Recognize cues

    The joint tells you what this is, and the chart tells you why tonight. The site is the first metatarsophalangeal joint — about 50% of first attacks and nearly 90% of patients over the disease course. The onset is abrupt, overnight, waking him from sleep, which is the sourced pattern. The joint is "warm, erythematous, and swollen… extremely tender to touch," and he cannot bear the sheet on it, which is the patient-level description in the source almost word for word. Then the risk factors, all from the same risk table: hypertension, obesity, stage 3 chronic kidney disease, and a thiazide diuretic. And then the precipitants, three of them at once: postoperative status, the diuretic, and perioperative fasting and dehydration. The two cues that must not be over-read are the temperature of 38.2 °C and the white count of 13,800, because gout produces both.

  2. 2
    Analyze cues

    Start with the number that looks reassuring and is not. The serum uric acid is 5.9 mg/dL — normal — and it excludes nothing: "approximately 50% of patients with acute gouty arthritis do NOT have an elevated serum uric acid level," and the measurement "is of NO DIAGNOSTIC VALUE" during an attack. Then the two numbers that look alarming and also settle nothing. Fever and leukocytosis occur in gout itself, "making it difficult to differentiate from septic arthritis," and the white count, ESR and C-reactive protein are "NONSPECIFIC and do NOT confirm or differentiate the diagnosis from septic arthritis." So the bedside cannot answer the question, and the question is serious, because a missed septic joint is destroyed within days. The deciding test is arthrocentesis — "essential to confirm the diagnosis and differentiate it from… septic arthritis, Lyme disease, or pseudogout" — and crystals alone will not close it, since "the presence of crystals in synovial fluid analysis does not rule out septic arthritis, as both conditions can coexist." Separately, count his flares: three in twelve months meets the STRONG ACR indication for urate-lowering therapy at two or more annually — so tonight is both a flare to treat and a decision to make.

  3. 3
    Prioritize

    First, get the joint aspirated, under sterile conditions, with Gram stain, culture and crystal analysis all sent — the infection question has to be open until it is answered, not assumed shut. Second, treat the flare now, choosing among the three equally strong first-line options on his patient factors. Third, the patient factors decide it for him: stage 3 chronic kidney disease makes an NSAID unattractive, and he is intermittently nil by mouth, which is precisely the situation in which ACR strongly recommends intramuscular, intravenous or intra-articular glucocorticoids. Fourth, the simple comfort measures that are actually recommended: topical ice as a conditional adjuvant, and the bedclothes kept off the foot. Fifth, the medication review — the thiazide is a named urate-raising drug and starting one is a named precipitant. Sixth, the urate-lowering decision, because three flares in a year is a strong indication and the admission is an opportunity rather than an obstacle. Seventh, hydration, which sits on three of his problems at once.

  4. 4
    Generate solutions

    Anticipate arthrocentesis under sterile technique, expecting "yellow and cloudy" fluid with neutrophil predominance and intracellular needle-shaped, negatively birefringent crystals, with Gram stain and culture sent regardless. Anticipate a glucocorticoid by an injectable route given his kidney function and nil-by-mouth status. Anticipate topical ice and a bed cradle. Anticipate HLA-B*5801 testing before allopurinol, conditionally recommended because he is African American. Anticipate allopurinol as first-line even with CKD — strongly recommended "for ALL patients, INCLUDING in those with CKD stage > 3" — started low, at 100 mg/day or less and lower still for his kidney function, with 50 mg/day or less considered. Anticipate concomitant anti-inflammatory prophylaxis continued 3 to 6 months, strongly recommended, because starting the drug can itself trigger a flare. Anticipate serial serum urate values titrating to below 6 mg/dL over weeks to months. And anticipate a review of the hydrochlorothiazide with the prescribing team, since it is both a urate-raising drug and a named precipitant.

  5. 5
    Take action

    Escalate with an SBAR that names the differential rather than the conclusion: "58-year-old man, postoperative day 2 after hip fracture repair, woken at three with an acutely red, hot, swollen right great toe he cannot bear a sheet on. Temperature 38.2, white count 13,800. Serum uric acid is 5.9, which does not exclude gout — about half of acute flares have a normal level and it has no diagnostic value during an attack. The picture fits gout and he has had three flares in twelve months, but fever and leukocytosis do not distinguish it from septic arthritis — requesting arthrocentesis with crystal analysis, Gram stain and culture before any intra-articular steroid. He has CKD stage 3 and is intermittently NPO, so an injectable glucocorticoid is the option his patient factors point to. He is on hydrochlorothiazide, a urate-raising drug." Then the nursing care: ice offered as an adjuvant, the foot kept clear of linen, hydration addressed, and analgesia given. Three traps to avoid: treating the normal uric acid as reassurance, injecting the joint before the infection question is answered, and waiting until discharge to have the urate-lowering conversation — the guideline conditionally recommends starting during the flare when the indication already exists, and his does.

  6. 6
    Evaluate

    Short term, success is a settling joint and an answered question. The aspirate shows intracellular needle-shaped negatively birefringent crystals and the culture returns negative — both results were needed, because crystals alone would not have excluded infection. Pain should ease substantially within the first day; the patient-facing benchmark is that prescribed treatment "should start to work within 2 days," against an untreated course of 3 to 14 days. Longer term, success is the conversation he leaves with. He is started on allopurinol at a low dose adjusted for his kidney function after HLA-B*5801 testing, with anti-inflammatory prophylaxis for 3 to 6 months, and he is told in advance that an early flare is expected and is not the drug failing. He is told the target is below 6 mg/dL, checked on serial values over weeks to months, that the therapy is continued indefinitely, and that it is not stopped for a flare. The diuretic is flagged for review. Lifestyle advice — alcohol, purines, high-fructose corn syrup, weight loss, all conditional — is given in the guideline’s own framing, without blame, and vitamin C is not recommended. And the point that carries the whole plan: when the toe stops hurting next week, the crystals will still be depositing.

Scenario — you’re the nurse

Work each question before revealing the answer. Rationales explain the wrong options too.

Orthopaedic ward · postoperative day 2, 0300

A 58-year-old man admitted after a fall and hip fracture repair. He has hypertension treated with hydrochlorothiazide, obesity, and stage 3 chronic kidney disease. He has been intermittently nil by mouth for procedures. He wakes at three in the morning with excruciating pain in the right great toe.

Right first metatarsophalangeal joint — red, hot, swollen, so tender he cannot tolerate the bedsheet on it
Vitals — T 38.2 °C · HR 104 · BP 148/86 · pain 10/10
Bloods — WBC 13,800/µL · serum uric acid 5.9 mg/dL · eGFR consistent with CKD stage 3
History — this is his third flare in twelve months · he is African American
Context — postoperative day 2 · on a thiazide · fasting and underhydrated around procedures
Q1 Multiple choice
A patient in an acute gout flare has a serum uric acid of 5.8 mg/dL. Which interpretation is correct?
  1. A. The normal level rules out gout; look for another cause of the hot joint.
  2. B. The level is normal, so urate-lowering therapy is not indicated in this patient.
  3. C. A serum uric acid during an acute attack has no diagnostic value; about half of patients in a flare have a normal level, and the diagnosis is made by joint aspiration.
  4. D. The level should be rechecked immediately to confirm the diagnosis.
Reveal answer & rationale
Answer: C
Quoted directly: "during acute gouty arthritis, the serum urate level may be high, normal, or low. Approximately 50% of patients with acute gouty arthritis do not have an elevated serum uric acid level. Serum uric acid measurement during an acute attack is of NO DIAGNOSTIC VALUE; it is most useful when checked AFTER the resolution of the flare" (C). Options A and D both treat the level as a diagnostic test, which it is not during a flare — the gold standard is arthrocentesis with compensated polarized light microscopy showing needle-shaped, negatively birefringent crystals. Option B confuses two different numbers: the indications for urate-lowering therapy are one or more subcutaneous tophi, radiographic damage attributable to gout, or two or more flares a year — a strong ACR 2020 recommendation — and none of them is a serum urate value.
Q2 Multiple choice
Synovial fluid from a hot, swollen knee shows needle-shaped, negatively birefringent intracellular crystals. The patient is febrile. What is the correct conclusion?
  1. A. Crystals confirm gout and exclude infection; cancel the cultures.
  2. B. The synovial white cell count will reliably separate gout from septic arthritis.
  3. C. Crystals confirm urate deposition but do not exclude septic arthritis, because both can coexist; Gram stain and culture still apply.
  4. D. The fever means this must be septic arthritis rather than gout.
Reveal answer & rationale
Answer: C
Stated explicitly and corroborated by a second source: "it is essential to note that THE PRESENCE OF CRYSTALS IN SYNOVIAL FLUID ANALYSIS DOES NOT RULE OUT SEPTIC ARTHRITIS, AS BOTH CONDITIONS CAN COEXIST," and "multiple etiologies can co-exist, and the presence of gout does not rule out the presence of concomitant infection" (C). Option B is contradicted directly: there is "considerable overlap in WBC counts and neutrophil percentages" between the two, "rendering these parameters unreliable for diagnosis." Option D over-reads the fever, since acute gout itself "may be associated with fever and leukocytosis." What does separate them is positive Gram stain and culture with low synovial glucose — which is why option A is the dangerous answer.
Q3 Select all that apply
Which elements of this man’s admission are sourced precipitants of a gout flare? Select all that apply.
  1. A. Postoperative status after hip fracture repair
  2. B. Hydrochlorothiazide
  3. C. Being kept fasting and underhydrated around procedures
  4. D. The flare being in the first metatarsophalangeal joint
  5. E. Being 58 years old
Reveal answer & rationale
Answer: A, B, C
Three are on the precipitant list and two are something else. The sourced list names "local trauma, alcohol binges, overeating or fasting, weight changes, use of diuretics, and initiation of urate-lowering drugs," and adds that "in a hospital setting, postoperative status or acute severe medical illnesses such as myocardial infarction, exacerbation of congestive heart failure, or cerebrovascular accident may precipitate attacks," with dehydration and starvation named alongside. So surgery (A), the thiazide (B) and the perioperative fasting and dehydration (C) are all triggers, and together they explain why this flare happened tonight rather than at any other time. The site (D) is not a trigger but the commonest location — the first metatarsophalangeal joint accounts for "approximately 50% of initial attacks" and nearly 90% of patients over the disease course, because temperature is one of the named factors in crystal formation and the great toe is the coolest, most distal joint. Age (E) is a risk factor for having the disease at all, not an event that sets off an attack: gout is "more common in men, especially as they get older." The distinction matters clinically — the triggers are the part you can act on.
Q4 Put in order
Put the nurse’s actions in order:
  1. A. Give the ordered glucocorticoid by an injectable route
  2. B. Ensure the joint is aspirated with Gram stain, culture and crystal analysis sent
  3. C. Offer topical ice and keep the bedclothes off the foot
  4. D. Raise the urate-lowering conversation, since this is his third flare in twelve months
Reveal answer & rationale
Correct order: B → A → C → D
Aspiration (B) comes first because it is the only action that answers a question which cannot wait and cannot be undone. Arthrocentesis is "essential to confirm the diagnosis and differentiate it from other conditions such as septic arthritis," and the cultures must be sent whatever the crystals show, because "the presence of crystals in synovial fluid analysis does not rule out septic arthritis, as both conditions can coexist" — and because a steroid injected into an infected joint is a far worse problem than a delayed gout diagnosis. Treating the flare (A) follows immediately, and his patient factors pick the agent for him: CKD stage 3 makes an NSAID unattractive and he is intermittently nil by mouth, which is the situation in which glucocorticoids by intramuscular, intravenous or intra-articular route are strongly recommended. Comfort measures (C) come next — topical ice is a conditional adjuvant recommendation, and bedclothes are kept off the affected joint, as patient advice puts it. The urate-lowering conversation (D) is last in sequence but not optional: two or more flares a year is a strong indication to start, and the guideline conditionally recommends starting during the flare rather than waiting for it to settle.
Q5 Multiple choice
Three months after starting allopurinol the patient has another flare and asks whether he should stop the tablet. Which response is correct?
  1. A. Stop the allopurinol until the flare settles, then restart it at the same dose.
  2. B. Stop the allopurinol permanently, since a flare on treatment shows it has failed.
  3. C. Keep taking it — a flare early in treatment is expected, and the therapy is continued to reach and hold a urate below 6 mg/dL.
  4. D. Double the allopurinol dose today to bring the flare under control faster.
Reveal answer & rationale
Answer: C
Continuing is what the guideline supports, and the early flare was predicted before it happened (C). Starting a urate-lowering drug is itself a named precipitant, which is exactly why concomitant anti-inflammatory prophylaxis is strongly recommended for 3 to 6 months — "shorter durations were associated with flares upon cessation of prophylaxis" — and why the starting dose is deliberately low, since "a lower starting dose of any ULT reduces the risk of flare associated with initiation." The therapy is strongly recommended to continue "to achieve and maintain an SU target of < 6 mg/dL," with high certainty of evidence. Interrupting it (A) has no support in the guideline at all; the 2020 recommendation runs the other way, conditionally recommending starting urate-lowering therapy DURING a flare. Stopping permanently (B) misreads the mechanism — the flare is crystals already deposited being mobilised, not the drug failing, and his indication has not changed. Doubling the dose (D) confuses the two jobs this class does: urate-lowering therapy treats the disease and is titrated by serial serum urate over weeks to months, while the flare itself is treated with colchicine, an NSAID or a glucocorticoid chosen on patient factors.

Common questions

What causes gout?
Common causes and risk factors include chronic kidney disease — the main exit for urate is renal, and ckd is both a cause and a consequence of the disease; acr notes that in ckd "there is a higher likelihood of gout progression and development of clinical tophi", hypertension, obesity, metabolic syndrome, diabetes and hyperlipidaemia — named as a group on the risk-factor table, with comorbidity prevalence rising as serum urate rises, thiazide and loop diuretics — named urate-raising drugs, and starting a diuretic is separately named as a flare precipitant, low-dose aspirin, cyclosporine, tacrolimus, pyrazinamide and ethambutol — the rest of the sourced urate-raising medication list, alcohol, ranked — "alcohol (beer > spirits > wine)"; limiting or abstaining was associated with serum urate 1.6 mg/dl lower, and more than one to two drinks with a 40% higher risk of a flare, and others.
What are the early signs of gout?
Early findings include A flare that settles by itself in a few days.
How does gout differ from rheumatoid arthritis, osteoarthritis and septic arthritis?
Joint pattern. Gout is monoarticular at onset, 85% to 90% lower limb, first metatarsophalangeal joint in about 50% of first attacks and nearly 90% over the disease course, with axial involvement uncommon. Rheumatoid arthritis "typically starts in small peripheral joints, is usually SYMMETRIC," involving MCP, PIP, MTP and wrist, while "the DIP joints are usually spared" and the lumbar spine is not involved. Osteoarthritis takes "proximal and distal interphalangeal joints, first carpometacarpal joints, hips, knees, first metatarsophalangeal joints, and lower cervical and lumbar spine" — note that the great toe appears in both the gout and the osteoarthritis distributions. Onset speed. Gout is abrupt, peaking in 12 to 24 hours; rheumatoid arthritis is insidious, with autoantibodies present "up to 10 years before the onset of clinical symptoms"; osteoarthritis degenerates under load over years. Stiffness and pain. Gout hurts at rest and on the lightest contact — the joint is "extremely tender to touch." Rheumatoid arthritis gives morning stiffness "more than 1 hour" that eases with movement. Osteoarthritis gives "morning stiffness lasting LESS THAN 30 minutes," with "pain… related to activity" that "resolves with rest." Nodules. Gout makes tophi — chalk-like urate deposits at joints, ears, finger pads, tendons and bursae, which may drain, and which are granulomas around crystals. Osteoarthritis makes Heberden and Bouchard nodes of bony enlargement. The trap: "WOMEN DEVELOP TOPHACEOUS DEPOSITS ON THE HEBERDEN NODES AND BOUCHARD NODES" — the two can occupy the same knuckle. Systemic features. Gout: fever, malaise, fatigue, occasionally mimicking sepsis. Rheumatoid arthritis: fatigue, fever, appetite loss and extra-articular organ involvement. Osteoarthritis: bony enlargement, crepitus, non-inflammatory effusions and limited range — no systemic features at all. The deciding test. Gout: needle-shaped, negatively birefringent intracellular crystals. Pseudogout: calcium pyrophosphate crystals. Septic arthritis: opaque yellow-green fluid, WBC above 50,000/µL, positive Gram stain and culture, low synovial glucose — with considerable overlap in cell counts, and crystals never excluding infection. Rheumatoid arthritis: serology and classification criteria, owned by that page.
Which uric acid number should I actually remember?
All three, with their owners — because they answer three different questions and mixing them up is the commonest error here. 6.8 mg/dL is the supersaturation threshold: "serum urate concentrations above 6.8 mg/dL result in SUPERSATURATION, increasing the risk of crystal deposition," and "regardless of the trigger, the final common pathway is urate supersaturation." It is physical chemistry, not policy. 8 mg/dL or more is one reference chapter’s figure for what is "diagnostic of hyperuricemia," with normal values given as "typically less than 6.8 mg/dL." And a high level on its own is not the disease: hyperuricemia "does not cause health problems for everyone." Below 6 mg/dL is the ACR 2020 treatment target — a strong recommendation with high certainty of evidence — set deliberately under the solubility limit so that crystals already deposited will dissolve. Do not call it "normal." And one number you will meet that the guideline does not endorse: a below 5 mg/dL target for visible tophi is not an ACR 2020 target; the guideline states that "due to lack of supporting evidence for additional specific thresholds, we do not define further thresholds for patients warranting more intensive ULT" — it deliberately removed the extra thresholds its own 2012 guideline carried.
Should allopurinol be stopped or delayed during a flare?
No — and the classic teaching that you must never start it during an attack is half wrong against the 2020 guideline. Take the three recommendations in order. ACR strongly recommends "CONTINUING ULT TO ACHIEVE AND MAINTAIN AN SU TARGET OF < 6 mg/dl over no target," with high certainty of evidence. It conditionally recommends "CONTINUING ULT INDEFINITELY over stopping ULT," with very low certainty — a weak recommendation the guideline itself grades as weak. And it conditionally recommends the opposite of the old rule: "When the decision is made that ULT is indicated WHILE the patient is experiencing a gout flare, we CONDITIONALLY recommend STARTING ULT DURING THE GOUT FLARE over starting ULT AFTER the gout flare has resolved." Nothing in the guideline supports interrupting therapy for a flare. What is true is that starting it can provoke one — "initiation of urate-lowering drugs" is a named precipitant — which is exactly why ACR strongly recommends concomitant anti-inflammatory prophylaxis continued 3 to 6 months rather than under three months, since "shorter durations were associated with flares upon cessation of prophylaxis," and why the starting dose is deliberately low: "a lower starting dose of any ULT reduces the risk of flare associated with initiation." Tell the patient this in advance, because an unexplained early flare is what makes people stop the drug.
How much does the gout diet actually do?
Less than its reputation, and the guideline says so itself. All four lifestyle recommendations are CONDITIONAL, not strong — limit alcohol, limit purines, limit high-fructose corn syrup, and use a weight-loss programme if overweight or obese, each "regardless of disease activity." Vitamin C supplementation is conditionally recommended AGAINST. The evidence behind them is honest about its limits: alcohol restriction was associated with urate "1.6 mg/dl LOWER" and more than one to two drinks with "a 40% higher risk of gout flare"; high-fructose corn syrup consumption was associated with higher incident gout; but a study "focused on LOW PURINE INTAKE DID NOT DEMONSTRATE LOWER SU." The mechanism agrees: removing dietary purines entirely for ten days lowers urate by only 25%. And the guideline gives an explicit instruction about how to have the conversation, which is more useful than the list: providers should "BE MINDFUL… AND ENSURE THAT DISCUSSIONS REGARDING DIETARY RECOMMENDATIONS ARE NOT MISINTERPRETED AS ‘PATIENT-BLAMING,’ AS PATIENTS FREQUENTLY FEEL STIGMATIZED WHEN DISCUSSING GOUT WITH THEIR PROVIDERS. DIETARY MODIFICATIONS LIKELY YIELD ONLY SMALL CHANGES IN SU CONCENTRATION, BUT DIETARY FACTORS MAY SERVE AS TRIGGERS FOR FLARES." So: diet moves flares more than it moves the number, the genetics matter more than either, and diet does not substitute for urate-lowering therapy.

Sources

Reviewed by Hae Suk Lee, RN

Educational summary for nursing students. Scenarios are fictional teaching cases. Always verify against current guidelines and your institution's protocols before acting in practice. Not medical advice.

Bookmark LearnDrugs.com?

Your saved pages are kept in this browser. Add LearnDrugs.com to your browser’s bookmarks to get back to them in one click.

Drag this link to your bookmarks bar: LearnDrugs.com

Or press Ctrl + D to bookmark the page you’re on.